Tags

Type your tag names separated by a space and hit enter

[Thromboxane A2 synthase inhibitor and receptor antagonist].
Nihon Rinsho 2001; 59(10):1986-91NR

Abstract

Thromboxane A2 (TxA2) plays an important role in asthma. TxA2 are newly generated after cellular activation and are produced by not only platelets but also eosinophils, basophils, alveolar macrophages, and neutrophils. Pharmacological actions of TxA2 include potent bronchoconstriction, increased microvascular leakage, impairment of mucociliary clearance, and induction of airway hyperresponsiveness. Recent study demonstrated that TxA2 receptor antagonist decreased the number of eosinophils in bronchial biopsy specimens, suggesting that this type of agent possesses anti-inflammatory actions in asthma. Furthermore, addition of TxA2 synthase inhibitor significantly increased the PEF values in the persistent asthmatic patients despite the treatment with moderate-dose of inhaled corticosteroids. Therefore, these results suggest that TxA2 synthase inhibitor and receptor antagonist are useful for the treatment with symptomatic patients who had already been treated with inhaled corticosteroids.

Authors+Show Affiliations

First Department of Internal Medicine, Showa University School of Medicine.No affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

11676143

Citation

Minoguchi, K, and M Adachi. "[Thromboxane A2 Synthase Inhibitor and Receptor Antagonist]." Nihon Rinsho. Japanese Journal of Clinical Medicine, vol. 59, no. 10, 2001, pp. 1986-91.
Minoguchi K, Adachi M. [Thromboxane A2 synthase inhibitor and receptor antagonist]. Nippon Rinsho. 2001;59(10):1986-91.
Minoguchi, K., & Adachi, M. (2001). [Thromboxane A2 synthase inhibitor and receptor antagonist]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 59(10), pp. 1986-91.
Minoguchi K, Adachi M. [Thromboxane A2 Synthase Inhibitor and Receptor Antagonist]. Nippon Rinsho. 2001;59(10):1986-91. PubMed PMID: 11676143.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Thromboxane A2 synthase inhibitor and receptor antagonist]. AU - Minoguchi,K, AU - Adachi,M, PY - 2001/10/26/pubmed PY - 2002/1/5/medline PY - 2001/10/26/entrez SP - 1986 EP - 91 JF - Nihon rinsho. Japanese journal of clinical medicine JO - Nippon Rinsho VL - 59 IS - 10 N2 - Thromboxane A2 (TxA2) plays an important role in asthma. TxA2 are newly generated after cellular activation and are produced by not only platelets but also eosinophils, basophils, alveolar macrophages, and neutrophils. Pharmacological actions of TxA2 include potent bronchoconstriction, increased microvascular leakage, impairment of mucociliary clearance, and induction of airway hyperresponsiveness. Recent study demonstrated that TxA2 receptor antagonist decreased the number of eosinophils in bronchial biopsy specimens, suggesting that this type of agent possesses anti-inflammatory actions in asthma. Furthermore, addition of TxA2 synthase inhibitor significantly increased the PEF values in the persistent asthmatic patients despite the treatment with moderate-dose of inhaled corticosteroids. Therefore, these results suggest that TxA2 synthase inhibitor and receptor antagonist are useful for the treatment with symptomatic patients who had already been treated with inhaled corticosteroids. SN - 0047-1852 UR - https://www.unboundmedicine.com/medline/citation/11676143/[Thromboxane_A2_synthase_inhibitor_and_receptor_antagonist]_ L2 - https://medlineplus.gov/asthma.html DB - PRIME DP - Unbound Medicine ER -